Triazoles as inhibitors of fatty acid synthase
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/41
A61K-031/4192
C07D-249/00
C07D-249/06
출원번호
US-0101970
(2011-05-05)
등록번호
US-8450350
(2013-05-28)
발명자
/ 주소
Bahadoor, Adilah
Castro, Alfredo C.
Chan, Lawrence K.
Keaney, Gregg F.
Nevalainen, Marta
Nevalainen, Vesa
Peluso, Stephane
Tibbitts, Thomas T.
출원인 / 주소
Infinity Pharmaceuticals, Inc.
대리인 / 주소
Jones Day
인용정보
피인용 횟수 :
0인용 특허 :
47
초록▼
Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the
Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
대표청구항▼
1. A compound of the formula (I): or a pharmaceutically acceptable form thereof;wherein:RA is selected from C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, 5-14 membered heteroaryl, and hydrogen;X is selected from —CN, —C(═O)N(RX2)2, and —CO2RX1 RB is selected from C6-14 aryl, 5-14 member
1. A compound of the formula (I): or a pharmaceutically acceptable form thereof;wherein:RA is selected from C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, 5-14 membered heteroaryl, and hydrogen;X is selected from —CN, —C(═O)N(RX2)2, and —CO2RX1 RB is selected from C6-14 aryl, 5-14 membered heteroaryl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, and 3-14 membered heterocyclyl;RC is selected from hydrogen, —OH, —ORC1, —ON(RC2)2, —N(RC2)2, —C(═O)RC1, —CHO, —CO2RC1, —C(═O)N(RC2)2, —C(═NRC2)ORC1, —C(═NRC2)N(RC2)2, —SO2RC1, —S(═O)RC1, —Si(RC1)3, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; orRB and RC together with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered carbocyclyl, heterocyclyl, aryl or heteroaryl ring;each RC1 and RX1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RC2 is, independently, selected from hydrogen, —OH, —ORC1, —N(RC3)2, —CN, —C(═O)RC1, —C(═O)N(RC3)2, —CO2RC1, —SO2RC1, —C(═NRC3)ORC1, —C(═NRC3)N(RC3)2, —SO2N(RC3)2, —SO2RC3, —SO2ORC3, —SORC1, —C(═S)N(RC3)2, —C(═O)SRC3, —C(═S)SRC3, —P(═O)2RC1, —P(═O)(RC1)2, —P(═O)2N(RC3)2, —P(═O)(NRC3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RX2 is, independently, selected from hydrogen, —OH, —ORX1, —N(RX3)2, —CN, —C(═O)RX1, —C(═O)N(RX3)2, —CO2RX1, —SO2RX1, —C(═NRX3)ORX1, —C(═NRX3)N(RX3)2, —SO2N(RX3)2, —SO2RX3, —SO2ORX3, —SORX1, —C(═S)N(RX3)2, —C(═O)SRX3, —C(═S)SRX3, —P(═O)2RX1, —P(═O)(RX1)2, —P(═O)2N(RX3)2, —P(═O)(NRX3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; andeach RC3 and RX3 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl. 2. The compound of claim 1, wherein X is —CN. 3. The compound of claim 1, wherein RA is selected from C6-14 aryl and 5-14 membered heteroaryl. 4. The compound of claim 3, wherein RA is C6-14 aryl. 5. The compound of claim 4, wherein RA is a group of the formula (ii): wherein R1, R2, R3, R4 and R5 are independently selected from hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ORA1, —ON(RA2)2, —N(RA2)2, —N(ORA3)RA3, —SH, —SRA1, —SSRA3, —C(═O)RA1, —CO2H, —CHO, —C(ORA3)2, —CO2RA1, —OC(═O)RA1, —OCO2RA1, —C(═O)N(RA2)2, —OC(═O)N(RA2)2, —NRA2C(═O)RA1, —NRA2CO2RA1, —NRA2C(═O)N(RA2)2, —C(═NRA2)ORA1, —OC(═NRA2)RA1, —OC(═NRA2)ORA1, —C(═NRA2)N(RA2)2, —OC(═NRA2)N(RA2)2, —NRA2C(═NRA2)N(RA2)2, —C(═O)NRA2SO2RA1, —NRA2SO2RA1, —SO2N(RA2)2, —SO2RA1, —SO2ORA1, —OSO2RA1, —S(═O)RA1, —OS(═O)RA1, —Si(RA1)3, —OSi(RA1)3—C(═S)N(RA2)2, —C(═O)SRA1, —C(═S)SRA1, —SC(═S)SRA1, —P(═O)2RA1, —OP(═O)2RA1, —P(═O)(RA1)2, —OP(═O)(RA1)2, —OP(═O)(ORA3)2, —P(═O)2N(RA2)2, —OP(═O)2N(RA2)2, —P(═O)(NRA2)2, —OP(═O)(NRA2)2, —NRA2P(═O)(ORA3)2, —NRA2P(═O)(NRA2)2, —P(RA3)2, —P(RA3)3, —OP(RA3)2, —OP(RA3)3, —B(ORA3)2, or —BRA1(ORA3), C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; or one or more of R1 and R2, R2 and R3, R3 and R4 or R4 and R5 are joined to form a C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl ring;each RA1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RA2 is, independently, selected from hydrogen, —OH, —ORA1, —N(RA3)2, —CN, —C(═O)RA1, —C(═O)N(RA3)2, —CO2RA1, —SO2RA1, —C(═NRA3)ORA1, —C(═NRA3)N(RA3)2, —SO2N(RA3)2, —SO2RA3, —SO2ORA3, —SORA1, —C(═S)N(RA3)2, —C(═O)SRA3, —C(═S)SRA3, —P(═O)2RA1, —P(═O)(RA1)2, —P(═O)2N(RA3)2, —P(═O)(NRA3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two R2 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach RA3 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RA3 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring. 6. The compound of claim 5, wherein each of R1, R2, R3, R4 and R5 is independently selected from hydrogen, halogen, —CN, —ORA1, —N(RA2)2, —CO2H, —CO2RA1, —C(═O)N(RA2)2, —SO2RA1, C1-10 alkyl, C2-10 alkynyl, 3-14 membered heterocyclyl, and C6-14 aryl; or one or more of R1 and R2, R2 and R3, R3 and R4 or R4 and R5 are joined to form a 5-14 membered heteroaryl ring. 7. The compound of claim 6, wherein each of R1, R2, R3, R4 and R5 is independently selected from hydrogen, halogen, —ORA1, C1-10 alkyl, and —C(═O)N(RA2)2; or R4 and R5 are joined to form a 5-14 membered heteroaryl ring. 8. The compound of claim 5, wherein RA is a group of the formula (ii-d): wherein one of R1 and R5 is selected from halogen, —CN, —ORA1, —N(RA2)2, —CO2H, —CO2RA1, —C(═O)N(RA2)2, —SO2RA1, C1-10 alkyl, C2-10 alkynyl, 3-14 membered heterocyclyl, and C6-14 aryl, and the other of R1 and R5 is selected from halogen, —CN, —ORA1, —N(RA2)2, —CO2H, —CO2RA1, —C(═O)N(RA2)2, —SO2RA1, C1-10 alkyl, C2-10 alkynyl, 3-14 membered heterocyclyl, and C6-14 aryl. 9. The compound of claim 8, wherein each of R1 and R5 is independently halogen. 10. The compound of claim 9, wherein each of R1 and R5 is independently selected from fluoro and chloro. 11. The compound of claim 1, wherein RB and Rc together with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered carbocyclyl, heterocyclyl, aryl or heteroaryl ring. 12. The compound of claim 11, wherein RB and Rc together with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered ring of the formula (xiv): wherein:Q is N, NR40, O, S, or CR41R42;m is 0, 1 or 2; andeach R41, R42, R43, R44, R45, R46, R47, R48, R49 and R50 is, independently, selected from hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ORF1, —ON(RF2)2, —N(RF2)2, —N(ORF3)RF3, —SH, —SRF1, —SSRF3, —C(═O)RF1, —CO2H, —CHO, —C(ORF3)2, —CO2RF1, OC(═O)RF1, —OCO2RF1, —C(═O)N(RF2)2, —OC(═O)N(RF2)2, —NRF2C(═O)RF1, —NRF2CO2RF1, —NRF2C(═O)N(RF2)2, —C(═NRF2)ORF1, —OC(═NRF2)RF1, —OC(═NRF2)ORF1, —C(═NRF2)N(RF2)2, —OC(═NRF2)N(RF2)2, —NRF2C(═NRF2)N(RF2)2, —C(═O)NRF2SO2RBC1, —NRF2SO2RF1, —SO2N(RF2)2, —SO2RF1, —SO2ORF1, —OSO2RF1, —S(═O)RF1, —OS(═O)RF1, —Si(RF1)3, —OSi(RF1)3—C(═S)N(RF2)2, —C(═O)SRF1, —C(═S)SRF1, —SC(═S)SRF1, —P(═O)2RF1, —OP(═O)2RF1, —P(═O)(RF1)2, —OP(═O)(RF1)2, —OP(═O)(ORF3)2, —P(═O)2N(RF2)2, —OP(═O)2N(RF2)2, —P(═O)(NRF2)2, —OP(═O)(NRF2)2, —NRF2P(═O)(ORF3)2, —NRF2P(═O)(NRF2)2, —P(RF3)2, —P(RF3)3, —OP(RF3)2, —OP(RF3)3, —B(ORF3)2, or —BRF1(ORF3), C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, 5-14 membered heteroaryl, -L-RD and —RE; or one or more of R47 and R49, R48 and R50, R49 and R41, R50 and R42, R41 and R45, R42 and R46, R45 and R43, and R46 and R44, are joined to form a double bond or a C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl ring; optionally wherein Q is N, then N and R49 or N and R46 are joined to form a double bond;R40 is selected from hydrogen, —OH, —ORF1, —N(RF3)2, —CN, —C(═O)RF1, —C(═O)N(RF3)2, —CO2RF1, —SO2RF1, —C(═NRF3)ORF1, —C(═RF3)N(RF3)2, —SO2N(RF3)2, —SO2RF3, —SO2ORF3, —SORF1, —C(═S)N(RF3)2, —C(═O)SRF3, —C(═S)SRF3, —P(═O)2RF1, —P(═O)(RF1)2, —P(═O)2N(RF3)2, —P(═O)(NRF3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or R49 and R40 or R40 and R45 are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;each RF1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RF2 is, independently, selected from hydrogen, —OH, —ORF1, —N(RF3)2, —CN, —C(═O)RF1, —C(═O)N(RF3)2, —CO2RF1, —SO2RF1, —C(═NRF3)ORF1, —C(═NRF3)N(RF3)2, —SO2N(RF3)2, —SO2RF3, —SO2ORF3, —S(═O)RF1, —C(═O)N(RF3)2, —C(═O)SRF3, —C(═S)SRF3, —P(═O)2RF1, —P(═O)(RF1)2, —P(═O)2N(RF3)2, —P(═O)(NRF3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RF2 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach RF3 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RF3 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;L is a covalent bond or a divalent C1-10 hydrocarbon chain, wherein one, two or three methylene units of L are optionally and independently replaced with one or more —O—, —S—, —NRB8—, —(C═NRB8)—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2—, divalent C3-10 carbocyclyl, divalent 3-14 membered heterocyclyl, divalent C6-14 aryl or divalent 5-14 membered heteroaryl group;RD is selected from —CN, —NO2, —N3, —SO2H, —SO3H, —C(═O)RB7, —CO2H, —CHO, —C(ORB9)2, —CO2RB7, —OC(═O)RB7, —OCO2RB7, —C(═O)N(RB8)2, —OC(═O)N(RB8)2, —NRB8C(═O)RB7, —NRB8CO2RB7, —NRB8C(═O)N(RB8)2, —C(═NRB8)ORB7, —OC(═NRB8)RB7, —OC(═NRB8)ORB7, —C(═NRB8)N(RB8)2, —OC(═NRB8)N(RB8)2, —NRB8C(═NRB8)N(RB8)2, —C(═O)NRB8SO2RB7, —NRB8SO2RB7, —SO2N(RB8)2, —SO2RB7, —SO2ORB7, —OSO2RB7, —S(═O)RB7, —OS(═O)RB7, —C(═S)N(RB8)2, —C(═O)SRB7, —C(═S)SRB7, —SC(═S)SRB7, —P(═O)2RB7, —OP(═O)2RB7, —P(═O)(RB7)2, —OP(═O)(RB7)2, —OP(═O)(ORB9)2, —P(═O)2N(RB8)2, —OP(═O)2N(RB8)2, —P(═O)(NRB8)2, —OP(═O)(NRB8)2, —NRB8P(═O)(ORB9)2, —NRB8P(═O)(NRB8)2, —B(ORB9)2, and —BRB7(ORB9);each RB7 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RB8 is, independently, selected from hydrogen, —OH, —ORB7, —N(RB9)2, —CN, —C(═O)RB7, —C(═O)N(RB9)2, —CO2RB7, —SO2RB7, —C(═NRB9)ORB7, —C(═NRB9)N(RB9)2, —SO2N(RB9)2, —SO2RB9, —SO2ORB9, —SORB7, —C(═S)N(RB9)2, —C(═O)SRB9, —C(═S)SRB9, —P(═O)2RB7, —P(═O)(RB7)2, —P(═O)2N(RB9)2, —P(═O)(NRB9)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB8 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach RB9 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB9 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;RE is selected from halogen, —OH, —ORB10, —ON(RB11)2, —N(RB11)2, —N(ORB12)RB12, —SH, —SRB10, —SSRB12, —OC(═O)RB10, —OCO2RB10, —OC(═O)N(RB11)2, —NRB11C(═O)RB10, —NRB11CO2RB10, —NRB11C(═O)N(RB11)2, —OC(═NRB11)RB10, —OC(═NRB11)ORB10, —OC(═NRB11)N(RB11)2, —NRB11C(═NRB11)N(RB11)2, —NRB11SO2RB10, —OSO2RB10, —OS(═O)RB10, —Si(RB10)3, —OSi(RB10)3, —SC(S)SRB10, —OP(═O)2RB10, —OP(═O)(RB10)2, —OP(═O)(ORB12)2, —OP(═O)2N(RB11)2, —OP(═O)(NRB11)2, —NRB11P(═O)(ORB12)2, —NRB11P(═O)(NRB11)2, —P(RB12)2, —P(RB12)3, —OP(RB12)2, —OP(RB12)3, 3-14 membered heterocyclyl and 5-14 membered heteroaryl, wherein the point of attachment of the 3-14 membered heterocyclyl or 5-14 membered heteroaryl group is on a nitrogen atom;each RB10 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each RB11 is, independently, selected from hydrogen, —OH, —ORB10, —N(RB12)2, —CN, —C(═O)RB10, —C(═O)N(RB12)2, —CO2RB10, —SO2RB10, —C(═NRB12)ORB10, —C(═NRB12)N(RB12)2, —SO2N(RB12)2, —SO2RB12, —SO2ORB12, —SORB10, —C(═S)N(RB12)2, —C(═O)SRB12, —C(═S)SRB12, —P(═O)2RB10, —P(═O)(RB10)2, —P(═O)2N(RB12)2, —P(═O)(NRB12)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB11 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach RB12 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB12 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring. 13. The compound of claim 12, wherein R47 and R49 are joined to form a C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl ring. 14. The compound of claim 13, wherein R47 and R49 are joined to form a C3-10 carbocyclyl. 15. The compound of claim 14, wherein Q is CR41R42. 16. The compound of claim 15, wherein m is 1. 17. The compound of claim 16, wherein each R41, R42, R43, R44, R45, R46, R48, and R50 is hydrogen; and R47 and R49 are joined to form a C3-10 carbocyclyl. 18. The compound of claim 17, wherein RB and RC together with the nitrogen (N) atom to which each is attached are joined to form a group of the formula (xiv-a): 19. The compound of claim 1, wherein RB is C6-14 aryl or 5-14 membered heteroaryl. 20. The compound of claim 19, wherein RB is C6-14 aryl. 21. The compound of claim 20, wherein RB is phenyl. 22. The compound of claim 21, wherein RB is unsubstituted phenyl. 23. The compound of claim 21, wherein RB is phenyl that is substituted with L-RD; wherein: L is a covalent bond or a divalent C1-10 hydrocarbon chain, wherein one, two or three methylene units of L are optionally and independently replaced with one or more —O—, —S—, —NRB8—, —(C═NRB8)—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2—, divalent C3-10 carbocyclyl, divalent 3-14 membered heterocyclyl, divalent C6-14 aryl or divalent 5-14 membered heteroaryl group; andRD is selected from —C(═O)RB7, —CO2H, —CHO, and —CO2RB7;wherein RB7 is selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl. 24. The compound of claim 23, wherein L is a covalent bond, and RD is —CO2H. 25. The compound of claim 1, wherein RC is an acyclic group. 26. The compound of claim 25, wherein RC is C1-10 alkyl. 27. The compound of claim 26, wherein RC is unsubstituted C1-10 alkyl. 28. The compound of claim 27, wherein RC is unsubstituted ethyl or unsubstituted isopropyl. 29. The compound of claim 1, wherein RB is C6-14 aryl or 5-14 membered heteroaryl; and RC is C1-10 alkyl. 30. The compound of claim 29, wherein RB is C6-14 aryl; and RC is C1-10 alkyl. 31. The compound of claim 1, wherein: RA is C6-14 aryl;RB and RC together with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered carbocyclyl, heterocyclyl, aryl or heteroaryl ring; andX is selected from —CN, —C(═O)N(RX2)2, and —CO2RX1. 32. The compound of claim 31, wherein X is —CN. 33. The compound of claim 1, wherein: RA is C6-14 aryl;RB is C6-14 aryl or 5-14 membered heteroaryl;RC is an acyclic group; andX is selected from —CN, —C(═O)N(RX2)2, and —CO2RX1. 34. The compound of claim 33, wherein RB is C6-14 aryl and RC is C1-10 alkyl. 35. The compound according to claim 33, wherein X is —CN. 36. A pharmaceutical composition comprising at least one compound of formula (I) according to claim 1, or a pharmaceutically acceptable form thereof; and at least one pharmaceutically acceptable excipient. 37. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (47)
Bessis, Anne-Sophie; Bonnet, Beatrice; Le Poul, Emmanuel; Rocher, Jean-Philippe; Epping-Jordan, Mark, Allosteric modulators of metabotropic glutamate receptors.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Kuhajda Francis P. ; Pasternack Gary R. ; Townsend Craig A. ; Mani Neelakandha S., Inhibition of fatty acid synthase as a means to reduce adipocyte mass.
Hadvary Paul (Biel-Benken CHX) Hochuli Erich (Arisdorf CHX) Kupfer Ernst (Basel CHX) Lengsfeld Hans (Reinach CHX) Weibel Ernst K. (Pratteln CHX), Leucine derivatives.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Newell,Martha Karen; Villobos Menuey,Elizabeth; Newell,Evan, Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.